一线[177Lu]Lu-PSMA-617单药治疗转移性激素敏感性前列腺癌病例
本文报告一例转移性前列腺癌患者,在拒绝雄激素剥夺治疗、化疗及前列腺局部治疗后,接受一线全身性[177Lu]Lu-PSMA-617治疗。该患者在接受2个剂量治疗后,原发癌灶及转移灶均表现出显著反应。
要点
- 患者拒绝ADT、化疗及局部治疗,选择一线[177Lu]Lu-PSMA-617。
- 2个剂量后原发灶与转移灶均显著反应。
- 提示[177Lu]Lu-PSMA-617一线治疗转移性激素敏感性前列腺癌的可能。
核心结论
- 一例转移性前列腺癌患者在一线接受[177Lu]Lu-PSMA-617单药治疗后,原发癌与转移灶均显著反应。
研究设计与样本
- 本文为个案报告,报告一例转移性前列腺癌患者接受一线[177Lu]Lu-PSMA-617治疗的经过。
主要发现
- 患者在接受2个剂量[177Lu]Lu-PSMA-617治疗后,原发癌灶及转移灶均表现出显著反应。
临床怎么用
- 对于拒绝ADT、化疗及局部治疗的转移性前列腺癌患者,可考虑一线[177Lu]Lu-PSMA-617治疗,但需注意此为个案经验。
局限性
- 本文为单例个案报告,证据级别有限,不能推广为普遍推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. 177Lu-vipivotide tetraxetan ([177Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen-expressing metastatic castration-resistant prostate adenocarcinoma. We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [177Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.
引用
- Giri VK, Kolodny GM, Garnick MB, et al. First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer. J Nucl Med. 2025. PMID: 40998725. doi:10.2967/jnumed.125.270704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。